PDF(Pubmed)
Abstract：
SARS‑CoV‑2 infection remains a hot topic; it is characterized by its multi-systemic involvement. Corticosteroid intake has been the subject of worldwide attention as a potentially effective treatment against coronavirus disease 2019 (COVID-19). Corticosteroids are registered on the WHO list of essential medicines, easily accessible for a low price, and particularly useful for different categories of people. The authors highlight the impact of corticosteroid administration for COVID-19 treatment on the occurrence of aseptic osteonecrosis in the femoral head. They also examine the pace of onset in comparison to corticosteroid usage unrelated to COVID-19. This article presents a patient with osteonecrosis of the femoral head after taking corticosteroid therapy in the treatment of COVID-19. The dose taken by the patient is 90 mg of dexamethasone equivalent to 600 mg of prednisone. The patient experienced the onset of OTA, and the duration of development was three months, indicating a relatively brief period. Comparison was made with data from the literature from 6 months to 1 year after taking corticosteroids in a context outside of COVID-19.
摘要：
SARS-CoV-2感染仍然是一个热门话题；它的特点是多系统参与。作为2019年冠状病毒病（COVID-19）的潜在有效治疗方法，皮质类固醇的摄入一直是全球关注的主题。皮质类固醇在世卫组织基本药物清单上注册，很容易以低廉的价格获得，对不同类别的人特别有用。作者强调了COVID-19治疗皮质类固醇对股骨头无菌性骨坏死发生的影响。他们还检查了与COVID-19无关的皮质类固醇使用的发病速度。本文介绍了1例接受糖皮质激素治疗后股骨头坏死的COVID-19。患者服用的剂量为90mg地塞米松，相当于600mg泼尼松。患者经历了OTA的发作，发展的持续时间是三个月，表明一个相对短暂的时期。与在COVID-19以外的情况下服用皮质类固醇6个月至1年的文献数据进行了比较。
